PTC Therapeutics Stock
StockStockPrice
Frequently asked questions
What is PTC Therapeutics's market capitalization?
What is the Earnings Per Share (EPS) for PTC Therapeutics?
What are the analyst ratings and target price for PTC Therapeutics's stock?
What is PTC Therapeutics's revenue over the trailing twelve months?
What is the EBITDA for PTC Therapeutics?
What is the free cash flow of PTC Therapeutics?
What is the 5-year beta of PTC Therapeutics's stock?
How many employees does PTC Therapeutics have, and what sector and industry does it belong to?
What is the free float of PTC Therapeutics's shares?
Financials
Market Cap
$3.46B5Y beta
0.63EPS (TTM)
-$5.94Free Float
75.32MRevenue (TTM)
$900.66MEBITDA (TTM)
$21.05MFree Cashflow (TTM)
-$186.27MPricing
Analyst Ratings
The price target is $36.82 and the stock is covered by 13 analysts.
Buy
5
Hold
4
Sell
4
Information
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
988
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker